Bristol-Myers Squibb Company SEC filings document the company’s pharmaceutical operating results, investor presentations, governance matters, registered securities and debt activity. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD presentations, annual-meeting vote results and other material events, including note offerings and tender-offer disclosures tied to the company’s capital structure.
The company’s proxy materials cover board elections, executive compensation, shareholder voting matters and corporate governance. Its registered securities disclosures include common stock, Celgene contingent value rights and multiple exchange-listed notes. Form 15 records also document the termination of registration for a $2 convertible preferred stock class with no holders of record, while other reporting obligations remain tied to listed securities.
David V. Elkins, Executive Vice President and Chief Financial Officer of Bristol-Myers Squibb Company (BMY), reported a sale of 56,000 shares of BMY common stock on 09/02/2025 at a weighted average price of $47.33 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2025, and the reported sale prices ranged from $47.075 to $47.820. After the transaction, Mr. Elkins beneficially owned 167,379 shares directly. In addition, the filing reports an indirect holding of 283.4 shares through the BMS Savings and Investment Program. The Form 4 was signed by an attorney-in-fact on 09/03/2025 and includes an undertaking to provide detailed per-price sale information upon request.
Wendy Short Bartie, EVP Corporate Affairs of Bristol-Myers Squibb Company (BMY), reported securities transactions on Form 4 showing restricted stock units vesting and shares withheld for taxes. On 09/01/2025, 1,235 restricted stock units converted into 1,235 shares of common stock (reported as acquisition at $0) under a vesting schedule that began 09/01/2023 and vests in four equal installments. Simultaneously, 632 shares were withheld to satisfy tax-withholding obligations at an indicated price of $47.18 per share. After these events, Ms. Bartie directly beneficially owned 5,669 shares.
Bristol-Myers Squibb Co. (BMY) filed a Form 144 notifying the proposed sale of 56,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE with an aggregate market value of $2,648,800.00. The filing reports total shares outstanding of 2,035,435,838 and an approximate sale date of 09/02/2025. The shares to be sold were acquired over 2021–2023 through stock option exercises and restricted stock vesting, with acquisition amounts listed by date (e.g., 2,976 on 08/12/2021; 19,326 on 09/13/2022). No securities were reported sold in the past three months.
Bristol-Myers Squibb (BMY) – Form 4 filing: EVP & Chief Medical Officer Cristian Massacesi reported the grant of 204,691 Restricted Stock Units (RSUs) on 08/01/2025. Each RSU converts into one share of BMY common stock upon vesting at no exercise cost.
Key terms:
- Vesting schedule: 25 % each year on the 1st–4th anniversaries of the grant date (first tranche 08/01/2026; final tranche 08/01/2029).
- Ownership after grant: Massacesi now holds 204,691 derivative securities directly.
- Transaction code: “A” (award) – no open-market purchase or sale occurred.
The award represents <0.01 % of BMY’s ~2.1 bn shares outstanding, so dilution is immaterial. The filing signals long-term incentive alignment but has no immediate earnings or cash-flow impact; therefore market effect should be minimal.
Bristol-Myers Squibb (BMY) filed an 8-K on 31-Jul-2025 to furnish, rather than file, its second-quarter 2025 earnings materials.
- Item 2.02: Exhibit 99.1 is the press release containing Q2-25 results.
- Item 7.01: Exhibit 99.2 is an investor presentation used for the 8:00 a.m. ET conference call.
- Both exhibits include non-GAAP figures with GAAP reconciliations; no financial metrics appear in the body of the 8-K itself.
- The furnished status limits Exchange Act §18 liability and prevents automatic incorporation into future filings unless specifically referenced.
- No other material transactions, governance changes or financing actions were disclosed.
The filing also lists NYSE-traded securities—common stock, 1.750 % notes due 2035, and Celgene CVRs—and contains standard emerging-growth-company and Regulation FD boilerplate.
Form 8-K – Item 5.02 (Departure of Certain Officers)
On 25 July 2025, Bristol-Myers Squibb Company (NYSE: BMY) reported that Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer & Head of Development, will step down from these roles effective 1 August 2025 and will fully exit the company on or before 1 November 2025. During the interim period he will act as an advisor.
Separation terms
- Cash severance governed by the U.S. Severance Benefits Plan.
- Pro-rated vesting of outstanding Market Share Units and Performance Share Units under the 2021 Stock Award & Incentive Plan.
- Prorated 2025 annual incentive under the Senior Executive Performance Incentive Plan.
No successor, strategic changes, or financial impact projections were disclosed. A related press release is furnished as Exhibit 99.1.